Clinical trials & pipeline

We are advancing a diverse and promising portfolio of clinically differentiated compounds through internal development and strategic external partnerships.

Phase 3
STELLAR-303
Colorectal Cancer
Phase 3
STELLAR-304
Non-Clear Cell Renal Cell Carcinoma
Phase 2/3
STELLAR-305
Squamous Cell Carcinoma of Head & Neck
Phase 1b/2
STELLAR-009
Multiple Solid Tumors, Renal Cell Carcinoma
Phase 1b/2
STELLAR-001
Multiple Solid Tumors
Phase 1b/2
JEWEL-101
Multiple Solid Tumors
Phase 1
Multiple Solid Tumors
Phase 1

Sairopa*

Multiple Solid Tumors
Asset/Program
  • Discovery/Preclinical Disc/Pre
  • IND IND
  • Phase 1 Phase 1
  • Phase 1b/2 Phase 1b/2
  • Pivotal Pivotal

CONTACT-02 (mCRPC)

CONTACT-02 (mCRPC)

COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC)

COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC)

Multi-TKI targeting MET/VEGFR/AXL/RET

Multi-TKI targeting MET/VEGFR/AXL/RET

Pivotal

CONTACT-02 (mCRPC)

CONTACT-02 (mCRPC)

Pivotal

COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC)

COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC)

Pivotal and Phase 1b/2

STELLAR-305 (SCCHN)

STELLAR-305 (SCCHN)

STELLAR-304 (nccRCC)

STELLAR-304 (nccRCC)

STELLAR-303 (CRC)

STELLAR-303 (CRC)

STELLAR-009 (Solid tumors, including advanced RCC)

STELLAR-009 (Solid tumors, including advanced RCC)

STELLAR-002 (Solid tumors)

STELLAR-002 (Solid tumors)

STELLAR-001 (Solid tumors)

STELLAR-001 (Solid tumors)

XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER

XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER

Pivotal

STELLAR-305 (SCCHN)

STELLAR-305 (SCCHN)

Pivotal

STELLAR-304 (nccRCC)

STELLAR-304 (nccRCC)

Pivotal

STELLAR-303 (CRC)

STELLAR-303 (CRC)

Phase 1b/2

STELLAR-009 (Solid tumors, including advanced RCC)

STELLAR-009 (Solid tumors, including advanced RCC)

Phase 1b/2

STELLAR-002 (Solid tumors)

STELLAR-002 (Solid tumors)

Phase 1b/2

STELLAR-001 (Solid tumors)

STELLAR-001 (Solid tumors)

Phase 1b/2

JEWEL-101 (Solid tumors)

JEWEL-101 (Solid tumors)

Next-generation TF-MTI ADC

Next-generation TF-MTI ADC

Phase 1b/2

JEWEL-101 (Solid tumors)

JEWEL-101 (Solid tumors)

Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)

USP1 inhibitor

USP1 inhibitor

Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)

Phase 1
Sairopa*

Option to acquire asset pending certain phase 1 results (Solid tumors)

Option to acquire asset pending certain phase 1 results (Solid tumors)

SIRPα-targeting mAb

SIRPα-targeting mAb

Phase 1

Option to acquire asset pending certain phase 1 results (Solid tumors)

Option to acquire asset pending certain phase 1 results (Solid tumors)

Discovery/Preclinical

Next-generation 5T4-MMAE ADC

Next-generation 5T4-MMAE ADC

Discovery/Preclinical
Discovery/Preclinical

PKMYT1 inhibitor

PKMYT1 inhibitor

Discovery/Preclinical
Discovery/Preclinical

Bispecific antibody targeting PD-L1 + NKG2A

Bispecific antibody targeting PD-L1 + NKG2A

Discovery/Preclinical
Discovery/Preclinical

Next-generation TF-TOPOi ADC

Next-generation TF-TOPOi ADC

Discovery/Preclinical
Discovery/Preclinical

ILT2-targeting mAb

ILT2-targeting mAb

Discovery/Preclinical
Discovery/Preclinical

IL13Rα2-TOPOi ADC

IL13Rα2-TOPOi ADC

Discovery/Preclinical

You are now leaving the exelixis.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.